Summary
Last month, the Department of Justice revived its enforcement of rules that restrict directors from serving on the boards of rival companies. GCR USA spoke with Stanford University professor Mark Lemley, who says a study he recently published shows that the Antitrust Division’s interventions have merely scratched the surface when it comes to interlocking directorates in the pharmaceuticals sector.
Read More